Zobrazeno 1 - 10 of 81 pro vyhledávání: '"C, Geretsegger"'
3
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland
Autor: C. Geretsegger, J. Fuger, Werner Kissling, H. Schubert, Josef Bäuml, Hans-Juergen Möller, Siegfried Kasper, F. Ferrero
Publikováno v: European Archives of Psychiatry and Clinical Neuroscience. 247:291-296
Results of a subanalysis of data from the multinational risperidone trial (RIS-INT-2) are reported. Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fdb1fced5b41770d2a99499402d4430
https://doi.org/10.1007/bf02922257
Zobrazit plný text záznamu
4
Paroxetine in the elderly depressed patient
Autor: M. Ludwig, C. Geretsegger, F. Böhmer
Publikováno v: International Clinical Psychopharmacology. 9:25-30
The efficacy of paroxetine and fluoxetine and their effects on cognitive and behavioural function were compared in a 6 week, double-blind, randomized study of 106 elderly depressed patients (aged 61 to 85 years). Antidepressant efficacy was assessed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e58fa375e071184bb0923548f66b092d
https://doi.org/10.1097/00004850-199400910-00004
Zobrazit plný text záznamu
8
Ipsapirone in the treatment of bulimia nervosa: an open pilot study
Autor: C, Geretsegger, K V, Greimel, I S, Roed, J M, Hesselink
Publikováno v: The International journal of eating disorders. 17(4)
Seventeen women who met the criteria for bulimia nervosa (DSM-III-R) were treated for 4 weeks in an open trial with ipsapirone, a partial 5-HT1A agonist. Bulimic symptoms diminished in 66.6% of the patients after only 1 week of treatment, 93.3% showe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::867f7960cded13d4ea0f6c4196e7603d
https://pubmed.ncbi.nlm.nih.gov/7620475
Zobrazit plný text záznamu
9
A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients
Autor: C H, Stuppaeck, C, Geretsegger, A B, Whitworth, H, Schubert, T, Platz, P, König, H, Hinterhuber, W W, Fleischhacker
Publikováno v: Journal of clinical psychopharmacology. 14(4)
The phenylpiperidine derivative paroxetine is a selective serotonin reuptake inhibitor. In a double-blind 6-week trial, paroxetine was compared with amitriptyline in hospitalized patients suffering from major depression (DSM-III). One hundred fifty-t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d9230fd7a061f60866e23bc414674f78
https://pubmed.ncbi.nlm.nih.gov/7962679
Zobrazit plný text záznamu
10
Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects
Autor: C, Geretsegger, F, Böhmer, M, Ludwig
Publikováno v: International clinical psychopharmacology. 9(1)
The efficacy of paroxetine and fluoxetine and their effects on cognitive and behavioural function were compared in a 6 week, double-blind, randomized study of 106 elderly depressed patients (aged 61 to 85 years). Antidepressant efficacy was assessed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c7bd749bd3be3975d596eb88650f464
https://pubmed.ncbi.nlm.nih.gov/8195578
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje